

oncology pipeline

IMMUNO-
ONCOLOGY

Assets

View More

Avelumab

anti-PD-L1 mAb

Development Phase

II

M6223*

anti-TIGIT mAb

Development Phase

I

II

Bintrafusp alfa

TGF-β “trap”/anti-PD-L1

Development Phase

II

M1069

Dual A2AR/A2BR antagonist

Development Phase

I

DNA DAMAGE
RESPONSE (DDR)

Assets

View More

Berzosertib (M6620)

ATR inhibitor

Development Phase

I

II

M1774

ATR inhibitor

Development Phase

I

Peposertib (M3814)

DNA-PK inhibitor

Development Phase

I

II

M4076

ATM inhibitor

Development Phase

I

ONCOGENIC
PATHWAYS

Assets

View More

Xevinapant

IAPs inhibitor

Development Phase

III

Tepotinib

MET kinase inhibitor

Development Phase

II

M1231

MUC1xEGFR

Development Phase

I

* Phase II study in combination with avelumab

Updated: May 2022

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.

Pipeline compounds are being investigated for the treatment of various diseases. Efficacy and safety of these compounds are still under investigation in various indications. Regulatory approval is dependent on the completion of the study programs and review by local regulatory authorities, and varies from country to country. Clinical trial information is available at www.clinicaltrials.gov.

©2022 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada. All product names are registered trademarks of Merck KGaA, Darmstadt, Germany or its affiliates.



IMMUNO-ONCOLOGY >

	TREATMENT	TUMOR SETTING	DEVELOPMENT PHASE		
			I	II	III
<div>avelumab¹ anti-PD-L1 mAb Learn More ></div>	Monotherapy and in combination with sacituzumab govitecan, M6223, or NKTR-255	Urothelial carcinoma 1L maintenance (JAVELIN Bladder Medley)			
<div>M6223 anti-TIGIT mAb Learn More ></div>	Monotherapy and in combination with bintrafusp alfa	Solid tumors			
	In combination with avelumab	Urothelial carcinoma 1L maintenance (JAVELIN Bladder Medley)			
<div>bintrafusp alfa TGF-β “trap”/anti-PD-L1 Learn More ></div>	Monotherapy	Cervical cancer 2L			
<div>M1069 Dual A2AR/A2BR antagonist Learn More ></div>	Monotherapy	Solid tumors			

1L, first-line treatment. 2L, second-line treatment.

¹Avelumab is being co-developed and co-marketed by Merck Healthcare KGaA, Darmstadt, Germany and Pfizer Inc.

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.

Pipeline compounds are being investigated for the treatment of various diseases. Efficacy and safety of these compounds are still under investigation in various indications. Regulatory approval is dependent on the completion of the study programs and review by local regulatory authorities, and varies from country to country. Clinical trial information is available at www.clinicaltrials.gov.

©2022 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada. All product names are registered trademarks of Merck KGaA, Darmstadt, Germany or its affiliates.



DNA DAMAGE RESPONSE (DDR) >

	TREATMENT	TUMOR SETTING	DEVELOPMENT PHASE		
			I	II	III
<div>berzosertib (M6620) ATR inhibitor Learn More ></div>	Combination with chemotherapy	SCLC 2L (DDRiver SCLC 250)			
		Solid tumors*			
<div>M1774 ATR inhibitor Learn More ></div>	Monotherapy and combination with niraparib	Solid tumors (DDRiver Solid Tumors 301)			
<div>peposertib (M3814) DNA-PK inhibitor Learn More ></div>	Combination with avelumab and radiotherapy	Solid tumors*			
	Combination with avelumab with or without radiotherapy	Solid tumors			
<div>M4076 ATM inhibitor Learn More ></div>	Monotherapy	Solid tumors (DDRiver Solid Tumors 410)			

2L, second-line treatment.

* EMD Serono-National Cancer Institute collaborative studies

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.

Pipeline compounds are being investigated for the treatment of various diseases. Efficacy and safety of these compounds are still under investigation in various indications. Regulatory approval is dependent on the completion of the study programs and review by local regulatory authorities, and varies from country to country. Clinical trial information is available at www.clinicaltrials.gov.

©2022 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada. All product names are registered trademarks of Merck KGaA, Darmstadt, Germany or its affiliates.



ONCOGENIC PATHWAYS



	TREATMENT	TUMOR SETTING	DEVELOPMENT PHASE		
			I	II	III
<div>xevinapant IAPs inhibitor Learn More</div>	Combination with chemoradiotherapy	Unresected LA SCCHN (TrilynX™)			
<div>tepotinib MET kinase inhibitor Learn More</div>	Combination with osimertinib	EGFR TKI-relapsed <i>MET</i> -amplified NSCLC (INSIGHT 2)			
<div>M1231 MUC1xEGFR Learn More</div>	Monotherapy	Solid tumors			

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.

Pipeline compounds are being investigated for the treatment of various diseases. Efficacy and safety of these compounds are still under investigation in various indications. Regulatory approval is dependent on the completion of the study programs and review by local regulatory authorities, and varies from country to country. Clinical trial information is available at www.clinicaltrials.gov.

©2022 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada. All product names are registered trademarks of Merck KGaA, Darmstadt, Germany or its affiliates.